πŸ‡ΊπŸ‡Έ FDA
Patent

US 11001613

TFPI inhibitors and methods of use

granted A61KA61K38/00A61K47/551

Quick answer

US patent 11001613 (TFPI inhibitors and methods of use) held by Takeda Pharmaceutical Company Limited expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K38/00, A61K47/551, A61K47/557, A61K47/60